Veterinary Research Forum
Vet Res Forum

MicroRNA-142-3p chemo-sensitizing breast cancer to docetaxel: apoptosis and cell cycle arrest induction, and migration suppression

Document Type : Original Article

Authors

Masoumeh Moradi-Arzeloo 1
Razeieh Dehghan 1
Behzad Mansoori 2, 3
Behzad Baradaran 2

1 Department of Pathobiology, Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran

2 Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

3 Department of Cancer and Inflammation Research, Institute for Molecular Medicine, University of Southern Denmark, Odense, Denmark

https://doi.org/10.30466/vrf.2024.2022533.4165
Abstract
Docetaxel (DTX) is widely utilized in breast cancer treatment. However, cancer cell resistance has limited its anti-tumor efficacy. Some molecules called microRNAs (miRNAs), acting like fine-tuned switches, can influence how breast cancer develops and spreads. We conducted a study to examine if augmenting breast cancer cells with a particular molecule, known as miRNA-142-3p, could improve the efficacy of a widely used treatment called DTX. The expression level of miR-142-3p was initially assessed in MDA-MB-468 cells. The miRNA transfection was performed to conduct additional experiments. The impact of a combined treatment involving DTX and miRNA-142-3p on both cell migration (by wound healing assay) and apoptosis (using annexin V/Propidium iodide staining) was examined. Cell viability was determined through the MTT assay, and gene expression was quantified using quantitative real-time polymerase chain reaction. The combined application of DTX and miRNA-142-3p resulted in a significant decrease in the expression of factors promoting tumor growth, such as SOX2, Octamer 4, HMGA2, Kruppel-like factor 4, and Bach-1. Additionally, the combination of miRNA-142-3p and DTX initiated apoptotic cell death. Moreover, the progression of breast cancer cells was impeded by inducing cell cycle arrest at the G1 phase. This combination also efficiently restrained the migration and invasion of breast cancer cells. The DTX or miRNA-142-3p alone can suppress malignant behavior and progression of breast cancer cells, but their combination elicits a synergistic effect that further enhances breast cancer inhibition. In summary, miRNA-142-3p transfection can be administered in conjunction with DTX therapy to enhance its cytotoxicity against breast cancer cells and prevent chemoresistance.

Keywords

Breast cancer
Cancer therapy
Chemotherapy
Docetaxel
MicroRNA-142-3p

Subjects

  1. Laborda-Illanes A, Sanchez-Alcoholado L, Dominguez-Recio ME, et al. Breast and gut microbiota action mechanisms in breast cancer pathogenesis and treatment. Cancers (Basel) 2020; 12(9): 2465. doi: 10.3390/cancers12092465.
  2. Richardson AK, Walker LC, Cox B, et al. Breast cancer and cytomegalovirus. Clin Transl Oncol 2020; 22(4): 585-602.
  3. Zhang KJ, Hu Y, Luo N, et al. miR‑574‑5p attenuates proliferation, migration and EMT in triple‑negative breast cancer cells by targeting BCL11A and SOX2 to inhibit the SKIL/TAZ/CTGF axis. Int J Oncol 2020; 56(5): 1240-1251.
  4. Zhao B, Song X, Guan H. CircACAP2 promotes breast cancer proliferation and metastasis by targeting miR-29a/b-3p-COL5A1 axis. Life Sci 2020; 244: 117179. doi: 10.1016/j.lfs.2019.117179.
  5. Zhou M, Dong M, Yang X, et al. The emerging roles and mechanism of m6a in breast cancer progression. Front Genet 2022; 13: 983564. doi: 10.3389/fgene. 2022.983564
  6. de Melo Gagliato D, Buzaid AC, Perez-Garcia J, et al. Immunotherapy in breast cancer: current practice and clinical challenges. BioDrugs 2020; 34(5): 611-623.
  7. Montemurro F, Nuzzolese I, Ponzone R. Neoadjuvant or adjuvant chemotherapy in early breast cancer? Expert Opin Pharmacother 2020; 21(9): 1071-1082.
  8. Hashemi M, Zandieh MA, Talebi Y, et al. Paclitaxel and docetaxel resistance in prostate cancer: molecular mechanisms and possible therapeutic strategies. Biomed Pharmacother 2023; 160: 114392. doi: 10.1016/j.biopha.2023.114392.
  9. Ahmed MB, Islam SU, Alghamdi AAA, et al. Phytochemicals as chemo-preventive agents and signaling molecule modulators: current role in cancer therapeutics and inflammation. Int J Mol Sci 2022; 23(24): 15765. doi: 10.3390/ijms232415765.
  10. Sanchez-Hernandez ES, Ochoa PT, Suzuki T, et al. Glucocorticoid receptor regulates and interacts with LEDGF/p75 to promote docetaxel resistance in prostate cancer cells. Cells 2023; 12(16): 2046. doi: 10.3390/cells12162046.
  11. Fan J, Zhang Z, Chen H, et al. Zinc finger protein 831 promotes apoptosis and enhances chemosensitivity in breast cancer by acting as a novel transcriptional repressor targeting the STAT3/Bcl2 signaling pathway. Genes Dis 2024; 11(1): 430-448.
  12. Jurczyk M, Kasperczyk J, Wrześniok D, et al. Nanoparticles loaded with docetaxel and resveratrol as an advanced tool for cancer therapy. Biomedicines 2022; 10(5): 1187. doi: 10.3390/biomedicines 10051187.
  13. Ashrafizadeh M, Ang HL, Moghadam ER, et al. MicroRNAs and their influence on the ZEB family: mechanistic aspects and therapeutic applications in cancer therapy. Biomolecules 2020; 10(7): 1040. doi: 10.3390/biom10071040.
  14. Ashrafizadeh M, Zarrabi A, Hushmandi K, et al. Lung cancer cells and their sensitivity/resistance to cisplatin chemotherapy: role of microRNAs and upstream mediators. Cell Signal 2021; 78: 109871. doi: 10.1016/j.cellsig.2020.109871.
  15. Shahverdi M, Hajiasgharzadeh K, Sorkhabi AD, et al. The regulatory role of autophagy-related miRNAs in lung cancer drug resistance. Biomed Pharmacother 2022; 148: 112735. doi: 10.1016/j.biopha. 2022.112735.
  16. Fu R, Tong JS. miR‐126 reduces trastuzumab resistance by targeting PIK3R2 and regulating AKT/mTOR pathway in breast cancer cells. J Cell Mol Med 2020; 24(13): 7600-7608.
  17. Zeng J, Li G, Xia Y, et al. miR-204/COX5A axis contributes to invasion and chemotherapy resistance in estrogen receptor-positive breast cancers. Cancer Lett 2020; 492: 185-196.
  18. Lv M, Zhang X, Jia H, et al. An oncogenic role of miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by targeting glucocorticoid receptor-α and cAMP/PKA pathways. Leukemia 2012; 26(4): 769-777.
  19. Chen HH, Huang WT, Yang LW, et al. The PTEN-AKT-mTOR/RICTOR pathway in nasal natural killer cell lymphoma is activated by miR-494-3p via PTEN but inhibited by miR-142-3p via Am J Pathol 2015; 185(5): 1487-1499.
  20. Wu L, Cai C, Wang X, et al. MicroRNA-142-3p, a new regulator of RAC1, suppresses the migration and invasion of hepatocellular carcinoma cells. FEBS Lett 2011; 585(9): 1322-1330.
  21. Li WQ, Zhao WC, Xin J, et al. MicroRNA-142-3p suppresses cell proliferation and migration in bladder cancer via J Biol Regul Homeost Agents 2020; 34(1). doi: 10.23812/19-460-A.
  22. Liang L, Fu J, Wang S, et al. MiR-142-3p enhances chemosensitivity of breast cancer cells and inhibits autophagy by targeting HMGB1. Acta Pharm Sin B 2020;10(6): 1036-1046.
  23. Lee J, Yesilkanal AE, Wynne JP, et al. Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism. Nature 2019; 568(7751): 254-258.
  24. Ou X, Gao G, Bazhabayi M, et al. MALAT1 and BACH1 are prognostic biomarkers for triple-negative breast cancer. J Cancer Res Ther 2019; 15(7): 1597-1602.
  25. Mansoori B, Mohammadi A, Asadzadeh Z, et al. HMGA2 and Bach‐1 cooperate to promote breast cancer cell malignancy. J Cell Physiol 2019; 234(10): 17714-17726.
  26. Mansoori B, Duijf PHG, Mohammadi A, et al. MiR-142- 3p targets HMGA2 and suppresses breast cancer malignancy. Life Sci 2021; 276: 119431. doi: 10.1016/j.lfs.2021.119431.
  27. Xu J, Fang X, Long L, et al. HMGA2 promotes breast cancer metastasis by modulating Hippo-YAP signaling pathway. Cancer Biol Ther 2021; 22(1): 5-11.
  28. Mansoori B, Duijf PHG, Mohammadi A, et al. Overexpression of HMGA2 in breast cancer promotes cell proliferation, migration, invasion and stemness. Expert Opin Ther Targets 2020; 24(3): 255-265.
  29. Hashemi M, Rashidi M, Hushmandi K, et al. HMGA2 regulation by miRNAs in cancer: affecting cancer hallmarks and therapy response. Pharmacol Res 2023; 190: 106732. doi: 10.1016/j.phrs.2023.106732.
  30. Qin C, Jin L, Li J, et al. Long noncoding RNA LINC02163 accelerates malignant tumor behaviors in breast cancer by regulating the MicroRNA-511-3p/HMGA2 axis. Oncol Res 2020; 28(5): 483-495.
  31. Ashrafizadeh M, Taeb S, Hushmandi K, et al. Cancer and SOX proteins: new insight into their role in ovarian cancer progression/inhibition. Pharmacol Res 2020; 161: 105159. doi: 10.1016/j.phrs.2020.105159.
  32. Liang S, Takahashi H, Hirose T, et al. NONO is a negative regulator of SOX2 Cancer Genomics Proteomics 2020; 17(4): 359-367.
  33. Xiao W, Zheng S, Xie X, et al. SOX2 promotes brain metastasis of breast cancer by upregulating the expression of FSCN1 and HBEGF. Mol Ther Oncolytics 2020; 17: 118-129.
  34. Gao FY, Li XT, Xu K, et al. c-MYC mediates the crosstalk between breast cancer cells and tumor microenvironment. Cell Commun Signal 2023; 21(1): 28. doi: 10.1186/s12964-023-01043-1.
  35. Lao-On U, Rojvirat P, Chansongkrow P, et al. c-Myc directly targets an over-expression of pyruvate carboxylase in highly invasive breast cancer. Biochim Biophys Acta Mol Basis Dis 2020; 1866(3): 165656. doi: 10.1016/j.bbadis.2019.165656.
  36. Wang S, Wang N, Zheng Y, et al. Caveolin-1 inhibits breast cancer stem cells via c-Myc-mediated metabolic reprogramming. Cell Death Dis 2020; 11(6): 450. doi: 10.1038/s41419-020-2667-x.
  37. Yu P, Li AX, Chen XS, et al. PKM2–c-Myc–Survivin cascade regulates the cell proliferation, migration, and tamoxifen resistance in breast cancer. Front Pharmacol 2020; 11: 550469. doi: 10.3389/fphar.2020.550469.
  38. Ji W, Zhang W, Wang X, et al. c-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc/miR-29b-3p/CDK6 axis. Cell Death Dis 2020; 11(9): 760. doi: 10.1038/s41419-020-02980-2.
  39. Liu N, Steer CJ, Song G. MicroRNA-206 enhances antitumor immunity by disrupting the communication between malignant hepatocytes and regulatory T cells in c-Myc mice. Hepatology 2022; 76(1): 32-47.
  40. Jahangiri R, Mosaffa F, EmamiRazavi A, et al. Increased expression of gankyrin and stemness factor Oct-4 are associated with unfavorable clinical outcomes and poor benefit of tamoxifen in breast carcinoma patients. Pathol Oncol Res 2020; 26(3): 1921-1934.
  41. Lu X, Yang F, Chen D, et al. Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways. Int J Biol Sci 2020;16(7): 1121-1134.
  42. Dorna D, Paluszczak J. Targeting cancer stem cells as a strategy for reducing chemotherapy resistance in head and neck cancers. J Cancer Res Clin Oncol 2023; 149(14): 13417-13435.
  43. Yao X, Tu Y, Xu Y, et al. Endoplasmic reticulum stress confers 5-fluorouracil resistance in breast cancer cell via the GRP78/OCT4/lncRNA MIAT/AKT pathway. Am J Cancer Res 2020; 10(3): 838-855.
  44. Chang YC, Yang YF, Chiou J, et al. Nonenzymatic function of Aldolase A downregulates miR-145 to promote the Oct4/DUSP4/TRAF4 axis and the acquisition of lung cancer stemness. Cell Death Dis 2020; 11(3):195. doi: 10.1038/s41419-020-2387-2.
Veterinary Research Forum
Volume 15, Issue 11
November 2024
Pages 629-643

  • Receive Date 08 February 2024
  • Revise Date 24 April 2024
  • Accept Date 29 June 2024

Home

Guide for Authors

Submit Manuscript

Reviewers

Contact Us